[Detection of thromboxane B2, 6-keto-prostaglandin F1alpha and anticardiolipin antibody in patients with obstructive sleep apnea-hypopnea syndrome].
OBJECTIVE
To observe the changes of thromboxane B(2) (TXB(2)), 6-keto-prostaglandin F1alpha (6-K-PGF1alpha) and anticardiolipin antibody (ACA) in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) before and after institution of nasal continuous positive airway pressure (nCPAP).


METHODS
Sixty cases of OSAHS confirmed by polysomnography (PSG) were selected as the trial group, and 20 normal donors without OSAHS were recruited as the control group. Nineteen patients with severe OSAHS were treated by nCPAP. Plasma levels of TXB(2), 6-K-PGF1alpha were detected by enzyme-linked immunosorbent assay (ELISA).


RESULTS
Plasma (serum) level of TXB(2) (ACA) was significantly higher in patients with moderate to severe OSAHS than that in control group (P < 0.01), and nCPAP therapy decreased its level significantly (P < 0.01). Plasma level of 6-K-PGF1alpha was significantly lower than that in the control group (P < 0.01), and nCPAP therapy increased its level significantly (P < 0.01). TXB(2) and ACA were correlated positively with AHI, and negatively with minimal oxygen saturation (P < 0.01). 6-K-PGF1alpha was correlated negatively with AHI, and positively with minimal oxygen saturation (P < 0.01).


CONCLUSIONS
The results indicate that patients with OSAHS are susceptible to thromboembolism disease. TXB(2), 6-K-PGF1alpha, ACA may be associated with the high prevalence of thromboembolism in patients with OSAHS. nCPAP therapy is effective in correcting TXB(2), 6-K-PGF1alpha, ACA.
Wu
Kan-jin
KJ
Department of Respiratory Medicine, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
An
Ze-yu
ZY
Guan
Ji-tao
JT
Zhang
Cong-min
CM
Feng
Hui-ping
HP
Yang
Li-jun
LJ
Wang
Bao-fa
BF
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D045422:Continuous Positive Airway Pressure; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000628:therapy*; D013923:Thromboembolism / Q000517:prevention & control; D013929:Thromboxane B2 / Q000097:blood*
D017153:Antibodies, Anticardiolipin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha